Glypican 5 is an interferon-beta response gene: A replication study

Multiple Sclerosis

Volumn 15, Issue 8, 2009, Pages 913-917

  Cenit M D C ^a   Blanco Kelly, F ^a   de las Heras, V ^a   Bartolome M ^a   de la Concha, E G ^a   Urcelay, E ^a   Arroyo, R ^a   Martínez Doncel, Alfonso ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

GPC5; HAPNL1; Interferon beta treatment; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; GENE PRODUCT; GLYPICAN; GLYPICAN 5; INTERFERON BETA SERINE; PROTEIN HAPLN1; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENE LOCUS; GENE REPLICATION; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATHOGENESIS; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DISABILITY EVALUATION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GLYPICANS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; ODDS RATIO; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEOGLYCANS; RECURRENCE; RISK ASSESSMENT; SPAIN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 69549135691     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509106509     Document Type: Article

References (14)

1. Hafler, DA, Slavik, JM, Anderson, DE, OConnor, KC, De Jager, P, Baecher-Allan, C. Multiple sclerosis. Immunol Rev 2005; 204: 208-231.
2. Marrie, RA. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol 2004; 3: 709-718.
3. Svejgaard, A. The immunogenetics of multiple sclerosis. Immunogenetics 2008; 60: 275-286.
4. Hafler, DA, Compston, A, Sawcer, S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851-862.
5. Weinstock-Guttman, B, Ramanathan, M, Zivadinov, R. Interferon-beta treatment for relapsing multiple sclerosis. Expert Opin Biol Ther 2008; 8: 1435-1447.
6. Markowitz, CE. Interferon-beta: Mechanism of action and dosing issues. Neurology 2007; 68: S8-S11.
7. Martinez, A, de las Heras, V, Mas Fontao, A, et al. An IFNG polymorphism is associated with interferon-beta response in Spanish MS patients. J Neuroimmunol 2006; 173: 196-199.
8. Byun, E, Caillier, SJ, Montalban, X, et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008; 65: 337-344.
9. ODoherty, C, Villoslada, P, Vandenbroeck, K. Pharmacogenomics of type I interferon therapy: A survey of response-modifying genes. Cytokine Growth Factor Rev 2007; 18: 211-222.
10. Leyva, L, Fernandez, O, Fedetz, M, et al. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol 2005; 163: 165-171.
11. Poser, CM, Paty, DW, Scheinberg, L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
12. Filmus, J, Capurro, M, Rast, J. Glypicans. Genome Biol 2008; 9: 224.
13. Jackson, SM, Nakato, H, Sugiura, M, et al. dally, a Drosophila glypican, controls cellular responses to the TGFbeta- related morphogen, Dpp. Development 1997; 124: 4113-4120.
14. Baranzini, SE, Wang, J, Gibson, RA, et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet 2009; 18(4): 767-778